Therapeuticsmd Inc (NASDAQ:TXMD) Sellers Reduced Their Shorts By 1.72%

June 27, 2018 - By Mark Williams

TherapeuticsMD, Inc. (NASDAQ:TXMD) Corporate Logo

During 2018 Q1 the big money sentiment decreased to 1.47. That’s change of 0.15, from 2017Q4’s 1.62. 17 investors sold all, 28 reduced holdings as TherapeuticsMD, Inc. ratio dived. 45 grew positions while 21 funds took positions. Funds hold 160.49 million shares thus 0.36% more from 2017Q4’s 159.91 million shares.
Grp One Trading L P stated it has 112,098 shs or 0.01% of all its holdings. D E Shaw And invested in 1.37 million shs or 0.01% of the stock. Sg Americas Secs Ltd Liability Company has invested 0% of its capital in TherapeuticsMD, Inc. (NASDAQ:TXMD). Gsa Prns Limited Liability Partnership has 117,700 shs. Raymond James reported 553,233 shs. Morgan Stanley stated it has 559,600 shs or 0% of all its holdings. Zeke Cap Advsrs Limited Liability Company accumulated 10,330 shs. Citigroup Inc invested 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Parallax Volatility Advisers L P holds 37,700 shs. Price T Rowe Inc Md owns 17.01 million shs. Rock Springs Capital Mgmt L P reported 1.17M shs. Jpmorgan Chase & holds 0.02% in TherapeuticsMD, Inc. (NASDAQ:TXMD) or 19.67 million shs. Teacher Retirement Systems Of Texas holds 0% or 38,372 shs in its capital. Balyasny Asset Management Limited Com stated it has 14,171 shs. Franklin has 0.03% invested in TherapeuticsMD, Inc. (NASDAQ:TXMD) for 10.56 million shs.

Therapeuticsmd Inc (NASDAQ:TXMD) showed a decrease of 1.72% in short interest. FINRA announced in June TXMD’s total 57.53M short interest. That’s 1.72% down from 58.53 million shares. Former TXMD’s position will need 31 days to restore. It has 1.84 million average volume. Therapeuticsmd Inc’s short interest float is 33.42%.

TXMD is reaching $6.87 during the last trading session, after decreased 1.72%.TherapeuticsMD, Inc. has volume of 348,937 shares. Since June 27, 2017 TXMD has risen 49.88% and is uptrending. The stock outperformed the S&P500 by 37.31%.

TherapeuticsMD, Inc. operates as a women??s health care product company.The firm is worth $1.49 billion. The firm makes and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, and natural menopause relief products under the vitaMedMD brand, as well as generic formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name.Currently it has negative earnings. The Company’s pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

There’s a substantial TherapeuticsMD, Inc. (NASDAQ:TXMD) news released by Nasdaq.com. It’s an item titled: “Here’s Why TherapeuticsMD Inc Jumped Today” on June 05, 2018.

TherapeuticsMD, Inc. (NASDAQ:TXMD) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.